Report

cardiovascular diagnostics market 2018 2024

Global Cardiovascular Diagnostics Market 2018-2024

pages Pages: 106
tables Tables: 32
charts Charts: 51
country Regions/Countries: 4 / 0
compaines Companies: 11
enqhours Enquiry Hours: 10
  • Get Free 10% Customization in this Report

COVID - 19

Covid impact updated reports at special price

Overview:

Cardiology diagnostics refer to tests performed to examine, check, and monitor the heart condition if an individual is suffering from cardiovascular diseases. There is an extensive range of diagnostic tests available such as ECG, invasive & non-invasive tests, cardiovascular autonomic reflex test, and other laboratory tests. A majority of the heart patients undergo a screening test, which is the first step in heart care. Diagnostic centers offer customized testing for each patient and ensure accurate diagnosis rapidly and cost-effectively. Cardiovascular diagnostics have created effective diagnostic solutions that support individuals in obtaining an accurate cardiac diagnosis, which help them to live longer and healthier. Most of the tests are performed to detect heart diseases well before an emergency event occurs. These tests are advanced, such as MRI, CT, ultrasound imaging, ECG, and offer point of care testing that provides effective results. These tests help to reduce the risk of mortality and offer strongly linked medical treatment in many emergency situations. Screening helps to determine the type of disease prior to the symptoms. The aim of screening tests is to provide the earliest and most desired treatment for the specific condition.

The cardiovascular diagnostics market is growing at a steady pace and is expected to grow at a rapid rate in the emerging countries. Factors, such as increasing lifestyle diseases, rise in smoking population, growing aging population, favorable reimbursements, and technological advancements in products, are driving the growth of the cardiovascular diagnostics market. However, the lack of awareness about diseases, stringent regulatory approval procedures, and risks associated with the procedure are hampering the market growth. The primary unmet need in the market is endoleaking, which increases the mortality rate.

The market is dominated by Abbott Laboratories, GE Healthcare, Philips Healthcare, Roche Diagnostics, and Bayer Healthcare, which have more than 85% of the share in the global cardiovascular diagnostics market.

Market Analysis: The global cardiovascular diagnostics market is estimated to witness a CAGR of 8.5% during the forecast period 2018–2024. The market is analyzed based on three segments, namely product type, end-users, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the cardiovascular diagnostics market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. The emerging markets have a high potential to grow owing to an increase in the number of patient population and focus toward healthcare infrastructure. The cardiovascular diagnostics market has the lowest penetration in the emerging markets, and most of the vendors are targeting to penetrate in countries such as India, China, Thailand, Vietnam, etc. However, the high cost of imaging modalities, expensive procedural costs, lack of skilled surgeons, lack of proper reimbursement policies, and lack of awareness about advanced diagnostic tools in the developing countries will have a significant impact on the overall market growth.

Product Analysis: The ECG segment is growing steadily and dominates the global cardiovascular diagnostics market with more than 37% of the total market share. Factors, such as increasing aging population, rise in the prevalence of CVDs, and growing adoption of POC testing devices are driving the market growth. The cardiac imaging segment is the most advanced and expected to overtake the ECG segment in coming years. The diagnosis and management of various cardiovascular diseases are increasingly growing with a large set of individuals depending on less-invasive imaging modalities such as CT angiography, cardiac magnetic resonance imaging (MRI), and cardiac radionuclide imaging such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). Advancements in medical imaging have increased the demand for image-guided diagnostics and surgical procedures, which have increased the usage of cardiac contrast media and radiopharmaceuticals.

Key Players: Abbott Laboratories, GE Healthcare, Philips Healthcare, Roche, Bayer Healthcare, and other predominate & niche players.

Competitive Analysis: The global cardiovascular diagnostics market is highly fragmented and has immense growth opportunities for vendors, especially in the developing regions. The market has the presence of many global, regional, and local players who are giving a stiff competition. The market is occupied by both global and local vendors who are competing to acquire the largest market share. Big players, such as Abbott Laboratories, GE Healthcare, Philips Healthcare, Roche, and Bayer Healthcare, are acquiring small players to increase their market share. The competitive environment in the market will intensify further with an increase in product/service extensions, product innovations, and M&As. They form strategic alliances for marketing or manufacturing of cardiovascular diagnostics devices.

Benefits: The report provides complete details about the usage and adoption rate of cardiovascular diagnostics for the treatment of various cardiac-related disorders. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Stakeholders:

cardiovascular diagnostics stakeholders

1              Industry Outlook

1.1          Industry Overview

1.2          Patient demographics

1.3          Healthcare Spending in the US

1.4          Definition: Cardiology Diagnostics

1.5          Why cardiovascular diagnostics?

1.6          Industry Trends

2              Report Outline

2.1          Report Scope

2.2          Report Summary

2.3          Research Methodology

2.4          Report Assumptions

3              Market Snapshot

3.1          Total Addressable Market (TAM)

3.2          Segmented Addressable Market (SAM)

3.3          Porter 5 (Five) Forces

4              Market Dynamics

4.1.1      Drivers

4.1.1.1   Increasing prevalence of cardiovascular diseases

4.1.1.2   Increasing geriatric population

4.1.1.3   Growing acceptance for minimally invasive endovascular surgeries

4.1.1.4   Increasing awareness towards point of care diagnostics in developing countries

4.1.1.1   Increase in healthcare spending

4.1.2      Restraints

4.1.2.1   High cost in installation and upgradation

4.1.2.2   Stringent regulations for approval

4.1.2.3   Intense competition among vendors

4.1.2.4   Lack of skilled healthcare professionals

4.1.2.5   Availability of alternative treatment procedure

4.1.3      Opportunities

4.1.3.1   Increase in demand for cardiac diagnostic imaging

4.1.3.2   Emergence of mHealth for improved outcome

4.1.3.3   Market expansion opportunities in emerging nations

4.1.3.4   Increasing number of insurance providers

4.1.4      DRO – Impact Analysis

4.1.5      Key Stakeholders

5              Product Types: Market Size & Analysis

5.1          Overview

5.2          ECG

5.2.1      Overview

5.3          Cardiac Imaging

5.3.1      Overview

5.4          Cardiac POC

5.4.1      Overview

5.5          Contrast Agents

5.5.1      Overview

6              End-user: Market Size and Analysis

6.1          Overview

6.2          Hospitals

6.3          Ambulatory Surgical Center

6.3.1      ASCs in the Americas

6.3.1.1   US

6.3.1.2   Canada

6.3.1.3   Mexico

6.3.2      ASCs in the EMEA Region

6.3.2.1   France

6.3.2.2   UK

6.3.2.3   Israel

6.3.2.4   Africa

6.3.3      ASCs in the APAC Region

6.3.3.1   Australia

6.3.3.2   India

6.3.3.3   China

6.4          Cardiac Centres

7              Regions: Market Size & Analysis

7.1          Overview

7.2          North America

7.2.1      Market Overview

7.3          Europe

7.3.1      Market Overview

7.4          APAC

7.4.1      Market Overview

7.4.2      Japan

7.4.3      China

7.4.4      India

7.5          Rest of the World

7.5.1      Market Overview

8              Competitive Landscape

8.1          Competitor Comparison Analysis

9              Vendor Profiles

9.1          Abbott Laboratories

9.1.1.1   Overview

9.1.2      Overview

9.1.3      Business Unit

9.1.4      Geographic Presence

9.1.5      Business Focus

9.1.6      SWOT Analysis

9.1.7      Business Strategy

9.2          F.Hoffmann-La Roche Ltd

9.2.1      Overview

9.2.2      Business Unit

9.2.3      Geographic Presence

9.2.4      Business Focus

9.2.5      SWOT Analysis

9.2.6      Business Strategy

9.3          GE Healthcare

9.3.1.1   Overview

9.3.1.2   Business unit

9.3.1.3   Business focus

9.3.1.4   SWOT analysis

9.4          Philips Healthcare

9.4.1.1   Overview

9.4.1.2   Business unit

9.4.1.3   Business focus

9.4.1.4   SWOT analysis

9.4.1.5   Business strategies

9.5          Siemens Healthineers Inc. (Siemens AG) 83

9.5.1      Overview

9.5.2      Business Units

9.5.3      Geographic Presence

9.5.4      Business Focus

9.5.5      SWOT Analysis

9.5.6      Business Strategy

10           Companies to watch for

10.1        Medtronic Plc

10.1.1    Key Highlights

10.1.2    Business Strategies

10.2        Hill-Rom Holdings, Inc

10.2.1    Overview

10.2.2    Key Highlights

10.2.3    Business Strategies

10.3        Qiagen N.V.

10.3.1    Overview

10.3.2    Key Highlights

10.3.3    Business Strategies

10.4        Boston Scientific Corp

10.4.1    Key Highlights

10.4.2    Business Strategies

10.4.3    Mortara Instruments

10.4.4    Key Highlights

10.4.5    Business Strategies

10.5        Instrumentation Laboratory (a Werfen company)

10.5.1    Overview

10.6        Becton Dickinson and Company

10.6.1    Overview

Annexure

Acronyms

TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY 19
TABLE 2 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET BY TYPES, 2017–2024 ($MILLION) 33
TABLE 3 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET BY END-USERS 44
TABLE 4 GLOBAL CARDIOVASCULAR DIAGNOSTICS MARKET REVENUE BY REGIONS FORECAST, 2017–2024 ($MILLION) 46
TABLE 5 DRO (NORTH AMERICA) 47
TABLE 6 DRO (EUROPE) 48
TABLE 7 DRO (APAC) 51
TABLE 8 DRO (REST OF THE WORLD) 53
TABLE 9 ABBOTT LABORATORIES: PRODUCT OFFERINGS 56
TABLE 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 57
TABLE 11 F. HOFFMANN-LA ROCHE: OFFERINGS 63
TABLE 12 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 64
TABLE 13 GE HEALTHCARE: PRODUCT OFFERINGS 70
TABLE 14 GE HEALTHCARE: RECENT DEVELOPMENTS 70
TABLE 15 PHILIPS HEALTHCARE: PRODUCT OFFERINGS 76
TABLE 16 PHILIPS HEALTHCARE: RECENT DEVELOPMENTS 76
TABLE 17 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 83
TABLE 18 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS 84
TABLE 19 MEDTRONIC PLC: SNAPSHOT 90
TABLE 20 MEDTRONIC PLC: RECENT DEVELOPMENTS 91
TABLE 21 HILL-ROM HOLDINGS, INC: SNAPSHOT 92
TABLE 22 HILL-ROM HOLDINGS, INC: RECENT DEVELOPMENTS 92
TABLE 23 QIAGEN N.V.: SNAPSHOT 94
TABLE 24 QIAGEN N.V.: RECENT DEVELOPMENTS 94
TABLE 25 BOSTON SCIENTIFIC CORP: SNAPSHOT 98
TABLE 26 BOSTON SCIENTIFIC CORP: RECENT DEVELOPMENTS 98
TABLE 27 MORTARA INSTRUMENTS: SNAPSHOT 100
TABLE 28 MORTARA INSTRUMENTS: RECENT DEVELOPMENTS 100
TABLE 29 INSTRUMENTATION LABORATORY: SNAPSHOT 101
TABLE 30 INSTRUMENTATION LABORATORY: RECENT DEVELOPMENTS 102
TABLE 31 BECTON DICKINSON AND COMPANY: SNAPSHOT 103
TABLE 32 BECTON DICKINSON AND COMPANY: RECENT DEVELOPMENTS 103

Research Framework

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting
Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources

Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources

Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.

outicon

Global Cardiovascular Diagnostics Market 2018-2024
Interested in this report?
Get your FREE sample now!

Select User License

$

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer 10% worth of FREE customization at the time of purchase

Speak to our analyst
Related Reports